Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma

NCT00193440 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Non-Hodgkins Lymphoma

Interventions

DRUG: Rituximab
DRUG: CHOP
DRUG: CVP
DRUG: Ibritumomab Tiuxetan

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]